Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 4,096 | 42% |
| 2020 | 33 | 4,212 | 45% |
| 2021 | 31 | 4,614 | 48% |
| 2022 | 37 | 4,910 | 51% |
| 2023 | 34 | 5,014 | 54% |
| 2024 | 41 | 5,936 | 56% |
| 2025 from claims | – | 7,012 6,435–7,419 | 57% |
| 2026 forecast | – | 7,685 6,762–8,869 | 57% |
| 2027 forecast | – | 8,387 7,170–9,994 | 58% |
| 2028 forecast | – | 9,150 7,635–11,204 | 58% |
| 2029 forecast | – | 9,982 8,153–12,519 | 59% |
| 2030 forecast | – | 10,888 8,723–13,953 | 60% |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 61% of the cases CMS names in Nevada; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 5% hospital outpatient, 95% office. The share outside the hospital has moved −5 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 513 | 68,597+18%/yr | +18%/yr | 20.1 | 91% | 127,400 in 2030+11%/yr |
| Arizona | 119 | 19,293+31%/yr | +31%/yr | 25.6 | 94% | 36,700 in 2030+11%/yr |
| Washington | 142 | 16,753+14%/yr | +14%/yr | 21.5 | 78% | 28,600 in 2030+9.3%/yr |
| Colorado | 85 | 11,013+29%/yr | +29%/yr | 22.2 | 86% | 21,300 in 2030+12%/yr |
| Oregon | 67 | 6,744+25%/yr | +25%/yr | 15.8 | 74% | 15,000 in 2030+14%/yr |
| Utah | 44 | 6,339+36%/yr | +36%/yr | 28.4 | 86% | 10,700 in 2030+9.2%/yr |
| Montana | 28 | 4,887+30%/yr | +30%/yr | 25.4 | 42% | 8,940 in 2030+11%/yr |
| Idaho | 36 | 3,935+37%/yr | +37%/yr | 19.0 | 46% | 8,300 in 2030+13%/yr |
| New Mexico | 26 | 3,176+18%/yr | +18%/yr | 13.6 | 77% | 6,050 in 2030+11%/yr |
| Alaska | 15 | 1,644+38%/yr | +38%/yr | 13.6 | 64% | 4,150 in 2030+17%/yr |
| Hawaii | 13 | 1,091+42%/yr | +42%/yr | 8.4 | 81% | 2,360 in 2030+14%/yr |
| Wyoming | 3 | 378+3.6%/yr | +3.6%/yr | 3.5 | 100% | 410 in 2030+1.5%/yr |
CGM & insulin pump management in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
Abbott leads with 38% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 6 companies reported engagement with Nevada’s surgeons worth $95K in consulting, speaking, meals and travel tied to these products, about $2,317 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.